These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36031856)

  • 21. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian hybrid dose-finding design in phase I oncology clinical trials.
    Yuan Y; Yin G
    Stat Med; 2011 Jul; 30(17):2098-108. PubMed ID: 21365672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2.
    Guo W; Wang SJ; Yang S; Lynn H; Ji Y
    Contemp Clin Trials; 2017 Jul; 58():23-33. PubMed ID: 28458054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group.
    Chen Z; Krailo MD; Sun J; Azen SP;
    Contemp Clin Trials; 2009 Mar; 30(2):123-8. PubMed ID: 19000782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A curve-free Bayesian decision-theoretic design for two-agent Phase I trials.
    Lee BL; Fan SK; Lu Y
    J Biopharm Stat; 2017; 27(1):34-43. PubMed ID: 26882373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
    Chen X; Zhang J; Jiang Q; Yan F
    J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
    Tighiouart M; Li Q; Rogatko A
    Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Keyboard design for phase I drug-combination trials.
    Pan H; Lin R; Zhou Y; Yuan Y
    Contemp Clin Trials; 2020 May; 92():105972. PubMed ID: 32151751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bayesian optimization design for finding a maximum tolerated dose combination in phase I clinical trials.
    Takahashi A; Suzuki T
    Int J Biostat; 2021 Apr; 18(1):39-56. PubMed ID: 33818029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies.
    Zhou Y; Lee JJ; Yuan Y
    Stat Med; 2019 Dec; 38(28):5299-5316. PubMed ID: 31621952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beyond the 3+3 method: expanded algorithms for dose- escalation in Phase I oncology trials of two agents.
    Braun TM; Alonzo TA
    Clin Trials; 2011 Jun; 8(3):247-59. PubMed ID: 21730075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials.
    Park M; Liu S; Yap TA; Yuan Y
    JAMA Netw Open; 2021 Feb; 4(2):e2037563. PubMed ID: 33595664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bayesian dose-finding phase I trial design incorporating historical data from a preceding trial.
    Takeda K; Morita S
    Pharm Stat; 2018 Jul; 17(4):372-382. PubMed ID: 29372582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.
    Riviere MK; Yuan Y; Dubois F; Zohar S
    Pharm Stat; 2014; 13(4):247-57. PubMed ID: 24828456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
    Pan H; Cheng C; Yuan Y
    Pharm Stat; 2020 Sep; 19(5):561-582. PubMed ID: 32248647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation.
    Xu J; Zhang D; Mu R
    BMC Med Res Methodol; 2022 Oct; 22(1):258. PubMed ID: 36183071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incorporating historical information to improve phase I clinical trials.
    Zhou Y; Lee JJ; Wang S; Bailey S; Yuan Y
    Pharm Stat; 2021 Nov; 20(6):1017-1034. PubMed ID: 33793044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose.
    Qiu Y; Zhao Y; Liu H; Cao S; Zhang C; Zang Y
    Contemp Clin Trials; 2023 Apr; 127():107139. PubMed ID: 36870476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts.
    Guo B; Yuan Y
    Stat Med; 2015 May; 34(10):1721-32. PubMed ID: 25626676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.